The study team found that AZD3514 worked reasonably well when hormone treatment had stopped working. But the side effects of feeling and being sick were a considerable concern.
This study closed in 2012 and these results were published in 2015.
About the trial
This summary combines the results of 2 studies of AZD3514.
Both studies were a
phase 1 study. A total 70 men took part in both studies. 8 of these men had AZD3514 with abiraterone.
The first few people had a low dose of AZD3514. The next few had a higher dose and so on until the highest safe dose was found.
Results
Overall the best dose of AZD3514 was below 2g twice a day.
The most common side effects were:
- feeling sick
- being sick
- tiredness
- lack of energy
- loss of appetite
- indigestion
- diarrhoea
- constipation
Of the 70 men, the
PSA blood level of 9 men had gone down by half (50%) or more.
At 6 months, 30 men had no sign of their cancer getting worse.
At a year, 15 men had no sign of their cancer getting worse.
Conclusion
The team concluded that the highest safe dose of AZD3514 did work reasonably well. But the side effects of this dose especially feeling and being sick made it unacceptable as a treatment.
Although the side effects mean that they don’t recommend AZD3514 as a treatment, they have learnt that this type of drug can work. And that further research into related drugs that don’t cause such severe side effects is deserved.
Where we got this information from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
peer reviewed 
) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.